TPM1

Across TCGA pan-cancer cohorts, TPM1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TPM1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TPM1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TPM1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where TPM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	IV	0.198	0.830	.024	22	view →
LSCC	DFS	Quartile	II,III,IV	0.506	0.939	.006	15	view →
PDAC	DFS	Quartile	III,IV	0.853	0.327	.016	4	view →
LUAD	DFS	Tertile	II,III,IV	0.376	0.736	.032	3	view →
HNSC	DFS	Tertile	All	0.941	1.000	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TPM1–CCRCC (OS)

Open the CCRCC breakdown →